Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study
Objectives: The COVID-19 pandemic continues, and evidence on infection- and vaccine-induced immunity is key. We assessed COVID-19 immunity and the neutralizing antibody response to virus variants across age groups in the Swiss population. Study Design: We conducted a cohort study in representative community-dwelling residents aged five years or older in southern Switzerland (total population 353,343), and we collected blood samples in July 2020 (in adults only, N = 646), November–December 2020 (N = 1457), and June–July 2021 (N = 885). Methods: We used a previously validated Luminex assay to measure antibodies targeting the spike (S) and the nucleocapsid (N) proteins of the virus and a high-throughput cell-free neutralization assay optimized for multiple spike protein variants. We calculated seroprevalence with a Bayesian logistic regression model accounting for the population’s sociodemographic structure and the test performance, and we compared the neutralizing activity between vaccinated and convalescent participants across virus variants. Results: The overall seroprevalence was 7.8% (95% CI: 5.4–10.4) by July 2020 and 20.2% (16.4–24.4) by December 2020. By July 2021, the overall seroprevalence increased substantially to 72.5% (69.1–76.4), with the highest estimates of 95.6% (92.8–97.8) among older adults, who developed up to 10.3 more antibodies via vaccination than after infection compared to 3.7 times more in adults. The neutralizing activity was significantly higher for vaccine-induced than infection-induced antibodies for all virus variants (all <i<p</i< values < 0.037). Conclusions: Vaccination chiefly contributed to the reduction in immunonaive individuals, particularly those in older age groups. Our findings on the greater neutralizing activity of vaccine-induced antibodies than infection-induced antibodies are greatly informative for future vaccination campaigns..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
International Journal of Environmental Research and Public Health - 20(2023), 3703, p 3703 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rebecca Amati [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Acquired immunity |
|---|
| doi: |
10.3390/ijerph20043703 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ080266576 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ080266576 | ||
| 003 | DE-627 | ||
| 005 | 20230310184226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230310s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijerph20043703 |2 doi | |
| 035 | |a (DE-627)DOAJ080266576 | ||
| 035 | |a (DE-599)DOAJc6565dd3cfcb406083e0f1b2022c912a | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Rebecca Amati |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives: The COVID-19 pandemic continues, and evidence on infection- and vaccine-induced immunity is key. We assessed COVID-19 immunity and the neutralizing antibody response to virus variants across age groups in the Swiss population. Study Design: We conducted a cohort study in representative community-dwelling residents aged five years or older in southern Switzerland (total population 353,343), and we collected blood samples in July 2020 (in adults only, N = 646), November–December 2020 (N = 1457), and June–July 2021 (N = 885). Methods: We used a previously validated Luminex assay to measure antibodies targeting the spike (S) and the nucleocapsid (N) proteins of the virus and a high-throughput cell-free neutralization assay optimized for multiple spike protein variants. We calculated seroprevalence with a Bayesian logistic regression model accounting for the population’s sociodemographic structure and the test performance, and we compared the neutralizing activity between vaccinated and convalescent participants across virus variants. Results: The overall seroprevalence was 7.8% (95% CI: 5.4–10.4) by July 2020 and 20.2% (16.4–24.4) by December 2020. By July 2021, the overall seroprevalence increased substantially to 72.5% (69.1–76.4), with the highest estimates of 95.6% (92.8–97.8) among older adults, who developed up to 10.3 more antibodies via vaccination than after infection compared to 3.7 times more in adults. The neutralizing activity was significantly higher for vaccine-induced than infection-induced antibodies for all virus variants (all <i<p</i< values < 0.037). Conclusions: Vaccination chiefly contributed to the reduction in immunonaive individuals, particularly those in older age groups. Our findings on the greater neutralizing activity of vaccine-induced antibodies than infection-induced antibodies are greatly informative for future vaccination campaigns. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a cohort study | |
| 650 | 4 | |a seroprevalence | |
| 650 | 4 | |a acquired immunity | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Giovanni Piumatti |e verfasserin |4 aut | |
| 700 | 0 | |a Giovanni Franscella |e verfasserin |4 aut | |
| 700 | 0 | |a Peter Buttaroni |e verfasserin |4 aut | |
| 700 | 0 | |a Anne-Linda Camerini |e verfasserin |4 aut | |
| 700 | 0 | |a Laurie Corna |e verfasserin |4 aut | |
| 700 | 0 | |a Sara Levati |e verfasserin |4 aut | |
| 700 | 0 | |a Marta Fadda |e verfasserin |4 aut | |
| 700 | 0 | |a Maddalena Fiordelli |e verfasserin |4 aut | |
| 700 | 0 | |a Anna Maria Annoni |e verfasserin |4 aut | |
| 700 | 0 | |a Kleona Bezani |e verfasserin |4 aut | |
| 700 | 0 | |a Antonio Amendola |e verfasserin |4 aut | |
| 700 | 0 | |a Cristina Fragoso Corti |e verfasserin |4 aut | |
| 700 | 0 | |a Serena Sabatini |e verfasserin |4 aut | |
| 700 | 0 | |a Marco Kaufmann |e verfasserin |4 aut | |
| 700 | 0 | |a Anja Frei |e verfasserin |4 aut | |
| 700 | 0 | |a Milo Alan Puhan |e verfasserin |4 aut | |
| 700 | 0 | |a Luca Crivelli |e verfasserin |4 aut | |
| 700 | 0 | |a Emiliano Albanese |e verfasserin |4 aut | |
| 700 | 0 | |a on behalf of the Corona Immunitas Ticino Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Environmental Research and Public Health |d MDPI AG, 2005 |g 20(2023), 3703, p 3703 |w (DE-627)DOAJ000006807 |x 16604601 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:3703, p 3703 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ijerph20043703 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/c6565dd3cfcb406083e0f1b2022c912a |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1660-4601/20/4/3703 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1661-7827 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1660-4601 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 3703, p 3703 | ||